Genomic Tests

4basecare’s Genomic Tests comprise a comprehensive suite of precision‑oncology assays designed to reveal actionable genomic alterations across a wide range of cancer types. These tests integrate tumor, germline, and liquid‑biopsy insights to support personalized treatment planning. By transforming complex genomic signals into clinically meaningful guidance, the test portfolio empowers oncologists to identify targeted therapies, anticipate resistance patterns, and optimize patient outcomes with greater confidence.

Features

• Broad portfolio covering tumor tissue, liquid biopsy, and hereditary cancer testing
• High‑depth sequencing for detecting mutations, fusions, copy‑number changes, and biomarkers
• Comprehensive gene panels tailored to common, rare, and understudied cancers
• Streamlined workflows for ordering, sample handling, and reporting
• Clear, clinician‑friendly reports highlighting actionable findings
• Integration of clinical context to enhance interpretation and therapy relevance

Capabilities

• Identifies actionable genomic alterations linked to targeted therapies and immunotherapies
• Supports biomarker‑based therapy selection, including resistance and sensitivity indicators
• Enables detection of minimal residual disease and tumor evolution through liquid biopsy
• Delivers hereditary cancer risk assessment via germline analysis
• Integrates genomic results with clinical and treatment data for contextual insights
• Scales across diverse oncology settings, from community clinics to specialized centers

Benefits

• Enhances precision treatment planning through comprehensive genomic intelligence
• Reduces trial‑and‑error decisions by highlighting therapy‑matched biomarkers
• Improves patient outcomes with individualized, data‑driven treatment strategies
• Provides earlier insights into disease progression and therapy response
• Strengthens confidence in clinical decisions through clear, actionable reporting
• Supports long‑term patient management across the full cancer‑care continuum